Financhill
Sell
25

ADAP Quote, Financials, Valuation and Earnings

Last price:
$0.45
Seasonality move :
26.85%
Day range:
$0.45 - $0.47
52-week range:
$0.44 - $1.65
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.64x
P/B ratio:
1.46x
Volume:
1.4M
Avg. volume:
1.1M
1-year change:
-69.14%
Market cap:
$116.9M
Revenue:
$60.3M
EPS (TTM):
-$0.18

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ADAP
Adaptimmune Therapeutics PLC
$8.4M -$0.15 4199.24% -9.44% $2.30
AUTL
Autolus Therapeutics PLC
$3M -$0.24 -61.82% -46.14% $10.45
BCYC
Bicycle Therapeutics PLC
$5.5M -$0.85 -55.59% -31.65% $29.55
BDRX
Biodexa Pharmaceuticals PLC
-- -- -- -- $17.97
TCBP
TC BioPharm (Holdings) PLC
-- -- -- -- --
VRNA
Verona Pharma PLC
$33.5M -$0.15 -- -89.84% $81.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ADAP
Adaptimmune Therapeutics PLC
$0.46 $2.30 $116.9M -- $0.00 0% 0.64x
AUTL
Autolus Therapeutics PLC
$1.82 $10.45 $484.3M -- $0.00 0% --
BCYC
Bicycle Therapeutics PLC
$9.98 $29.55 $690.6M -- $0.00 0% 16.46x
BDRX
Biodexa Pharmaceuticals PLC
$2.12 $17.97 $1.4M -- $0.00 0% 1.91x
TCBP
TC BioPharm (Holdings) PLC
$1.75 -- $897.8K -- $0.25 0% --
VRNA
Verona Pharma PLC
$66.56 $81.00 $5.7B -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ADAP
Adaptimmune Therapeutics PLC
38.4% 2.439 20.51% 3.54x
AUTL
Autolus Therapeutics PLC
-- 3.987 -- 17.97x
BCYC
Bicycle Therapeutics PLC
-- 0.789 -- 13.61x
BDRX
Biodexa Pharmaceuticals PLC
-- 0.756 -- 1.20x
TCBP
TC BioPharm (Holdings) PLC
-- -1.548 -- --
VRNA
Verona Pharma PLC
37.04% -0.759 3.06% 10.24x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ADAP
Adaptimmune Therapeutics PLC
-- -$14.7M -55.22% -67.8% -38.33% -$54.9M
AUTL
Autolus Therapeutics PLC
-- -$67.7M -80.74% -80.74% -331.28% -$86.3M
BCYC
Bicycle Therapeutics PLC
-- -$67.1M -25.48% -26.21% -1426.21% -$9.8M
BDRX
Biodexa Pharmaceuticals PLC
-- -- -160.77% -160.77% -- --
TCBP
TC BioPharm (Holdings) PLC
-- -$2.6M -- -- -- -$3.5M
VRNA
Verona Pharma PLC
$34.6M -$17.8M -60.44% -88.7% -41.57% -$29.4M

Adaptimmune Therapeutics PLC vs. Competitors

  • Which has Higher Returns ADAP or AUTL?

    Autolus Therapeutics PLC has a net margin of -43.07% compared to Adaptimmune Therapeutics PLC's net margin of -522.15%. Adaptimmune Therapeutics PLC's return on equity of -67.8% beat Autolus Therapeutics PLC's return on equity of -80.74%.

    Company Gross Margin Earnings Per Share Invested Capital
    ADAP
    Adaptimmune Therapeutics PLC
    -- -$0.06 $129.9M
    AUTL
    Autolus Therapeutics PLC
    -- -$0.31 $582M
  • What do Analysts Say About ADAP or AUTL?

    Adaptimmune Therapeutics PLC has a consensus price target of $2.30, signalling upside risk potential of 403.61%. On the other hand Autolus Therapeutics PLC has an analysts' consensus of $10.45 which suggests that it could grow by 483.64%. Given that Autolus Therapeutics PLC has higher upside potential than Adaptimmune Therapeutics PLC, analysts believe Autolus Therapeutics PLC is more attractive than Adaptimmune Therapeutics PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    ADAP
    Adaptimmune Therapeutics PLC
    3 2 0
    AUTL
    Autolus Therapeutics PLC
    8 0 0
  • Is ADAP or AUTL More Risky?

    Adaptimmune Therapeutics PLC has a beta of 2.520, which suggesting that the stock is 152.023% more volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 2.067, suggesting its more volatile than the S&P 500 by 106.723%.

  • Which is a Better Dividend Stock ADAP or AUTL?

    Adaptimmune Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptimmune Therapeutics PLC pays -- of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ADAP or AUTL?

    Adaptimmune Therapeutics PLC quarterly revenues are $40.9M, which are larger than Autolus Therapeutics PLC quarterly revenues of $10.1M. Adaptimmune Therapeutics PLC's net income of -$17.6M is higher than Autolus Therapeutics PLC's net income of -$82.1M. Notably, Adaptimmune Therapeutics PLC's price-to-earnings ratio is -- while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptimmune Therapeutics PLC is 0.64x versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ADAP
    Adaptimmune Therapeutics PLC
    0.64x -- $40.9M -$17.6M
    AUTL
    Autolus Therapeutics PLC
    -- -- $10.1M -$82.1M
  • Which has Higher Returns ADAP or BCYC?

    Bicycle Therapeutics PLC has a net margin of -43.07% compared to Adaptimmune Therapeutics PLC's net margin of -1398.44%. Adaptimmune Therapeutics PLC's return on equity of -67.8% beat Bicycle Therapeutics PLC's return on equity of -26.21%.

    Company Gross Margin Earnings Per Share Invested Capital
    ADAP
    Adaptimmune Therapeutics PLC
    -- -$0.06 $129.9M
    BCYC
    Bicycle Therapeutics PLC
    -- -$0.75 $793.1M
  • What do Analysts Say About ADAP or BCYC?

    Adaptimmune Therapeutics PLC has a consensus price target of $2.30, signalling upside risk potential of 403.61%. On the other hand Bicycle Therapeutics PLC has an analysts' consensus of $29.55 which suggests that it could grow by 196.05%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Bicycle Therapeutics PLC, analysts believe Adaptimmune Therapeutics PLC is more attractive than Bicycle Therapeutics PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    ADAP
    Adaptimmune Therapeutics PLC
    3 2 0
    BCYC
    Bicycle Therapeutics PLC
    5 3 0
  • Is ADAP or BCYC More Risky?

    Adaptimmune Therapeutics PLC has a beta of 2.520, which suggesting that the stock is 152.023% more volatile than S&P 500. In comparison Bicycle Therapeutics PLC has a beta of 1.121, suggesting its more volatile than the S&P 500 by 12.137%.

  • Which is a Better Dividend Stock ADAP or BCYC?

    Adaptimmune Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bicycle Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptimmune Therapeutics PLC pays -- of its earnings as a dividend. Bicycle Therapeutics PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ADAP or BCYC?

    Adaptimmune Therapeutics PLC quarterly revenues are $40.9M, which are larger than Bicycle Therapeutics PLC quarterly revenues of $3.7M. Adaptimmune Therapeutics PLC's net income of -$17.6M is higher than Bicycle Therapeutics PLC's net income of -$51.9M. Notably, Adaptimmune Therapeutics PLC's price-to-earnings ratio is -- while Bicycle Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptimmune Therapeutics PLC is 0.64x versus 16.46x for Bicycle Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ADAP
    Adaptimmune Therapeutics PLC
    0.64x -- $40.9M -$17.6M
    BCYC
    Bicycle Therapeutics PLC
    16.46x -- $3.7M -$51.9M
  • Which has Higher Returns ADAP or BDRX?

    Biodexa Pharmaceuticals PLC has a net margin of -43.07% compared to Adaptimmune Therapeutics PLC's net margin of --. Adaptimmune Therapeutics PLC's return on equity of -67.8% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.

    Company Gross Margin Earnings Per Share Invested Capital
    ADAP
    Adaptimmune Therapeutics PLC
    -- -$0.06 $129.9M
    BDRX
    Biodexa Pharmaceuticals PLC
    -- -- $6M
  • What do Analysts Say About ADAP or BDRX?

    Adaptimmune Therapeutics PLC has a consensus price target of $2.30, signalling upside risk potential of 403.61%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.97 which suggests that it could grow by 753.38%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Adaptimmune Therapeutics PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Adaptimmune Therapeutics PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    ADAP
    Adaptimmune Therapeutics PLC
    3 2 0
    BDRX
    Biodexa Pharmaceuticals PLC
    1 0 0
  • Is ADAP or BDRX More Risky?

    Adaptimmune Therapeutics PLC has a beta of 2.520, which suggesting that the stock is 152.023% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.489, suggesting its more volatile than the S&P 500 by 48.943%.

  • Which is a Better Dividend Stock ADAP or BDRX?

    Adaptimmune Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptimmune Therapeutics PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ADAP or BDRX?

    Adaptimmune Therapeutics PLC quarterly revenues are $40.9M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Adaptimmune Therapeutics PLC's net income of -$17.6M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Adaptimmune Therapeutics PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptimmune Therapeutics PLC is 0.64x versus 1.91x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ADAP
    Adaptimmune Therapeutics PLC
    0.64x -- $40.9M -$17.6M
    BDRX
    Biodexa Pharmaceuticals PLC
    1.91x -- -- --
  • Which has Higher Returns ADAP or TCBP?

    TC BioPharm (Holdings) PLC has a net margin of -43.07% compared to Adaptimmune Therapeutics PLC's net margin of --. Adaptimmune Therapeutics PLC's return on equity of -67.8% beat TC BioPharm (Holdings) PLC's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ADAP
    Adaptimmune Therapeutics PLC
    -- -$0.06 $129.9M
    TCBP
    TC BioPharm (Holdings) PLC
    -- -$5.07 --
  • What do Analysts Say About ADAP or TCBP?

    Adaptimmune Therapeutics PLC has a consensus price target of $2.30, signalling upside risk potential of 403.61%. On the other hand TC BioPharm (Holdings) PLC has an analysts' consensus of -- which suggests that it could grow by 2642.86%. Given that TC BioPharm (Holdings) PLC has higher upside potential than Adaptimmune Therapeutics PLC, analysts believe TC BioPharm (Holdings) PLC is more attractive than Adaptimmune Therapeutics PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    ADAP
    Adaptimmune Therapeutics PLC
    3 2 0
    TCBP
    TC BioPharm (Holdings) PLC
    0 0 0
  • Is ADAP or TCBP More Risky?

    Adaptimmune Therapeutics PLC has a beta of 2.520, which suggesting that the stock is 152.023% more volatile than S&P 500. In comparison TC BioPharm (Holdings) PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock ADAP or TCBP?

    Adaptimmune Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TC BioPharm (Holdings) PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.25 per share. Adaptimmune Therapeutics PLC pays -- of its earnings as a dividend. TC BioPharm (Holdings) PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ADAP or TCBP?

    Adaptimmune Therapeutics PLC quarterly revenues are $40.9M, which are larger than TC BioPharm (Holdings) PLC quarterly revenues of --. Adaptimmune Therapeutics PLC's net income of -$17.6M is lower than TC BioPharm (Holdings) PLC's net income of -$2.5M. Notably, Adaptimmune Therapeutics PLC's price-to-earnings ratio is -- while TC BioPharm (Holdings) PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptimmune Therapeutics PLC is 0.64x versus -- for TC BioPharm (Holdings) PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ADAP
    Adaptimmune Therapeutics PLC
    0.64x -- $40.9M -$17.6M
    TCBP
    TC BioPharm (Holdings) PLC
    -- -- -- -$2.5M
  • Which has Higher Returns ADAP or VRNA?

    Verona Pharma PLC has a net margin of -43.07% compared to Adaptimmune Therapeutics PLC's net margin of -92.29%. Adaptimmune Therapeutics PLC's return on equity of -67.8% beat Verona Pharma PLC's return on equity of -88.7%.

    Company Gross Margin Earnings Per Share Invested Capital
    ADAP
    Adaptimmune Therapeutics PLC
    -- -$0.06 $129.9M
    VRNA
    Verona Pharma PLC
    94.44% -$0.40 $324.9M
  • What do Analysts Say About ADAP or VRNA?

    Adaptimmune Therapeutics PLC has a consensus price target of $2.30, signalling upside risk potential of 403.61%. On the other hand Verona Pharma PLC has an analysts' consensus of $81.00 which suggests that it could grow by 21.7%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Verona Pharma PLC, analysts believe Adaptimmune Therapeutics PLC is more attractive than Verona Pharma PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    ADAP
    Adaptimmune Therapeutics PLC
    3 2 0
    VRNA
    Verona Pharma PLC
    5 0 0
  • Is ADAP or VRNA More Risky?

    Adaptimmune Therapeutics PLC has a beta of 2.520, which suggesting that the stock is 152.023% more volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.392, suggesting its less volatile than the S&P 500 by 60.803%.

  • Which is a Better Dividend Stock ADAP or VRNA?

    Adaptimmune Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptimmune Therapeutics PLC pays -- of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ADAP or VRNA?

    Adaptimmune Therapeutics PLC quarterly revenues are $40.9M, which are larger than Verona Pharma PLC quarterly revenues of $36.7M. Adaptimmune Therapeutics PLC's net income of -$17.6M is higher than Verona Pharma PLC's net income of -$33.8M. Notably, Adaptimmune Therapeutics PLC's price-to-earnings ratio is -- while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptimmune Therapeutics PLC is 0.64x versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ADAP
    Adaptimmune Therapeutics PLC
    0.64x -- $40.9M -$17.6M
    VRNA
    Verona Pharma PLC
    -- -- $36.7M -$33.8M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Is Ford Stock Undervalued Amid the EV Transition?
Is Ford Stock Undervalued Amid the EV Transition?

There is a lot going on in the electric vehicle…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
52
RGC alert for Mar 18

Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.

Buy
63
EXOD alert for Mar 18

Exodus Movement [EXOD] is down 3.96% over the past day.

Sell
45
MNPR alert for Mar 18

Monopar Therapeutics [MNPR] is up 0.93% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock